The central bank now expects that GDP in 2025 will grow by 2 percent, compared to the expectation in March which was 3.6 percent.
The reduction is a result of revisions of historical data, tariffs on goods exported to the USA and lower expectations for the pharmaceutical industry, according to the central bank.
The central bank is also lowering its GDP forecasts for 2026 and 2027.
Novo Nordisk, which manufactures the weight loss preparations Wegovy and Ozempic, has lowered its growth forecasts several times this year. Including after losing its leading position on the US market to competitor Eli Lilly.
Earlier in September, Novo announced that it will cut 9,000 jobs – of which around 5,000 are in Denmark.
